PAR 1.96% 25.0¢ paradigm biopharmaceuticals limited..

Ann: NEW FINANCIAL YEAR UPDATE, page-100

  1. 18 Posts.
    lightbulb Created with Sketch. 21
    PAR listed as a SELL in today's Herald Sun:

    "The drug developer to treat osteoarthritis has seen its stock bounce back strongly but with concerns, such as the quality of its phase 2b trial, positions can be trimmed"

    What a load of BS
 
watchlist Created with Sketch. Add PAR (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.